Page 74 - Read Online

Kepka. J Cancer Metastasis Treat 2020;6:12 I http://dx.doi.org/10.20517/2394-4722.2020.35 Page 3 of 4

during WBRT, more data is needed to confirm whether there is truly a long-standing neuroprotective effect
[17]
of this drug for patients undergoing WBRT. Results for the two other agents were inconclusive .

The Guest Editor and Contributors for this special issue of Journal of Cancer Metastasis and Treatment hope
that clinicians will find these articles interesting and useful for their daily practice.

DECLARATIONS
Authors’ contributions
The author contributed solely to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Gaspar LE, Prabhu RS, Hdeib A, McCracken DJ, Lasker GF, et al. Congress of neurologic surgeons systematic review and evidence-
based guideline hihges on the role of whole brain radiation therapy in adults with newly diagnosed metastatic brain tumors. Neurosurg
2019;84:e159-62.
2. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or
surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011;29:134-41.
3. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, et al. Effects of radiosurgery alone vs radiosurgery with whole brain radiation
therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 2016;316:401-9.
4. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, et al. Postoperative stereotactic radiosurgery compared with whole brain
radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet
Oncol 2017;18:1049-60.
5. Komosinska K, Kepka L, Niwinska A, Pietrzak L, Wierzchowski M, et al. Prospective evaluation of the palliative effect of whole-brain
radiotherapy in patients with brain metastases and poor performance status. Acta Oncol 2010;49:382-8.
6. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, et al. Dexamethasone and supportive care with or without whole brain
radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy
(QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016;388:2004-14.
7. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation
Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
8. Kepka L, Cieslak E, Bujko K, Wierzchowski M. Results of the whole-brain radiotherapy for patients with brain metastases from lung
cancer: the RTOG RPA intra-classes analysis. Acta Oncol 2005;44:389-98.
9. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, et al. Summary report on the graded prognostic assessment: an accurate and facile
diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-25.
10. Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, et al. The effect of gene alterations and tyrosine kinase inhibition on survival and
cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys 2016;96:406-13.
11. Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, et al. Hippocampal avoidance during whole-brain radiotherapy for patients with brain